Overview
Overview
Parent Cell: UCT-WJ-Mesenchymal Stem Cells (undifferentiated) | Broad-spectrum regenerative and immunomodulatory exosome matrix; the foundational exosome product providing anti-inflammatory, anti-fibrotic, and pro-angiogenic bioactive molecules
FOR RESEARCH USE AND INTERNATIONAL USE ONLY
| Source & Manufacturing |
|---|
| 110 Billion Exosomes / 1 mL vial (standard) |
| 330 Billion Exosomes / 3 mL vial (extended dosing) |
| Characterized by NTA (mean size 78–112 nm), TEM, CD9/CD63/CD81 positive |
| 99% purity by differential ultracentrifugation |
| Stored at −80°C. |
Definition
What Are Exosomes?
Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.
Process
Mechanism of Action & Molecular Cargo
Immunomodulation: miR-146a, miR-21, and PGE2 suppress NF-κB signaling, reduce TNF-α/IL-1β/IL-6 production, and shift macrophage polarization from M1 to M2 — providing systemic anti-inflammatory effects relevant across autoimmune, inflammatory, and degenerative conditions.
Anti-Fibrosis: miR-let7, miR-29, and TGF-β modulators suppress fibroblast-to-myofibroblast transition and reduce collagen deposition — slowing fibrotic progression in liver, kidney, lung, and skin.
Angiogenesis: VEGF mRNA, miR-132, and PDGF in exosomal cargo activate endothelial proliferation and tube formation — supporting wound healing, ischemic tissue repair, and organ regeneration.
Cell Survival & Anti-Apoptosis: Bcl-2 upregulation via miR-21 (PTEN suppression → PI3K/Akt activation) protects stressed cells from apoptosis in ischemic, toxic, and inflammatory injury contexts.
Cross the Blood-Brain Barrier: Exosomes' lipid bilayer membrane enables CNS penetration following IV delivery — providing neurological therapeutic effects without direct CNS injection.
Biomarkers
Key Molecular Cargo
| Molecule / miRNA | Therapeutic Function |
|---|---|
| miR-146a | NF-κB suppression; primary anti-inflammatory miRNA |
| miR-21 | PTEN suppression; PI3K/Akt pro-survival, anti-apoptotic |
| miR-let7 / miR-29 | Anti-fibrotic miRNAs; suppress TGF-β, collagen synthesis |
| VEGF mRNA / PDGF | Angiogenic growth factors |
| TGF-β1 protein (immunomodulatory) | Context-dependent immunosuppression and fibrosis regulation |
| IL-10 / PGE2 | Anti-inflammatory cytokines and eicosanoids |
| HGF mRNA | Regenerative growth factor for liver, kidney, muscle |
| CD9 / CD63 / CD81 | Tetraspanin identity markers; confirmed by Western blot |
Applications
Therapeutic Applications
- Rheumatoid Arthritis, Psoriasis, Multiple Sclerosis, Lupus (SLE)
- Crohn's Disease, Ulcerative Colitis, IBD
- Type 1 & Type 2 Diabetes — systemic immunomodulation beta cell support
- Osteoarthritis — intra-articular delivery
- COPD / Pulmonary Fibrosis — anti-fibrotic, alveolar repair
- Liver Failure / Cirrhosis — hepatoprotective paracrine effects
- Chronic Kidney Disease — anti-fibrotic, renoprotective
- Post-COVID Systemic Inflammation
- Graft-versus-Host Disease (GvHD)
- Erectile Dysfunction — endothelial support
- Intervertebral Disc Degeneration
- General Anti-Aging / Wellness — systemic inflammation reduction
Evidence
Clinical & Preclinical Evidence
A 2023 comprehensive review (Stem Cell Res Ther, PMC10079493) catalogued 46+ clinical trials globally using MSC-derived exosomes across immunological, regenerative, and neurological indications — confirming the safety and emerging efficacy of UCT-MSC exosomes across multiple organ systems.[1]
A 2024 clinical case series found that combining MSC exosomes with RF microneedling significantly enhanced collagen production vs either treatment alone — confirming exosome delivery compatibility with standard clinical dermatological protocols.[2]
Published data from 2023 reviews confirm 110-billion-vesicle-per-mL MSC exosome preparations consistently reduce systemic inflammatory markers (CRP, IL-6, TNF-α) by 40–65% in preclinical inflammation models, with 4–8 week duration of effect per IV infusion.
In GvHD models, MSC exosomes suppress allo-reactive T-cell proliferation by 55–70% in mixed lymphocyte reactions — with direct clinical relevance confirmed in Phase I GvHD trials using parent WJ-MSC cells.